Novartis first half net profits up 29 percent / Photo: © AFP
-
Neo Nontso Reveals Anele Mdoda’s Calm Demeanor During Wedding Prep
-
NCLT Chennai Orders Insolvency Proceedings Against Orchid Pharma Founder K Raghavendra Rao
-
How Mystery Bounty Poker Tournaments Spread from Curiosity to Mainstream
-
Inflation Breach and Bond Yields Spark Rate Hike Fears for December
-
Market Buzz: Meesho Stake Sale, Clean Max’s ₹50,000 Crore Investment and Corporate Updates
-
Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q2
-
The 20 Most Shocking Documentaries Ranked: From Elizabeth Holmes to Man on Wire
-
Below Deck alumnus João Franco and brother arrested after fatal Turkey fight
-
Ole Miss inquiry expands after video and monkey-noise allegations
-
General Hospital actor Randall England dies at 75
-
Bunnie XO artwork taken down from Jelly Roll’s Nashville bar
-
London museum removes Russell Brand hair exhibit after rape conviction
-
Arlington sentinel rebukes Pete Hegseth entourage for laughter near memorial
-
Yella Beezy sentenced to life for arranging rapper Mo3’s murder
-
Late Late Show Line-Up Announced Featuring Nicola Coughlan and TJ Reid
-
Kylie Jenner employee describes closet ordeal and pepper-spray incident
-
Authorities to identify Montauk Mary and five other Long Island cold-case victims
-
Davante Adams injury deepens Los Angeles Rams receiver shortage
-
Barbie sequel negotiations stall over reported $25 million pay packages
-
João Franco’s earlier post draws attention after arrest over fatal Turkey brawl
-
Bath & Body Works launches buy-one-get-one-free candle offer
Novartis first half net profits up 29 percent
Swiss pharmaceuticals giant Novartis posted Thursday a 29 percent increase in first-half net income, at $7.6 billion -- and unveiled its new chief financial officer.
The Basel-based firm's net sales increased 12 percent to nearly $27.3 billion between January and June, it said in a statement.
Generic competition reduced its sales by two percent.
In the first half of 2025, sales of Entresto -- its flagship drug to treat chronic heart failure -- reached $4.6 billion, up 22 percent. Generic versions are expected to hit the market in the second half of the year.
Novartis chief executive Vas Narasimhan also pointed to the strong performance of other treatments such as Kisqali, for breast cancer, and Pluvicto, for prostate cancer.
The group also announced a change in its financial leadership due to take place next year.
Mukul Mehta, the head of business planning and analysis in digital finance and tax, will become the new chief financial officer in March.
He will succeed Harry Kirsch, who has held the position since 2013. Kirsch is retiring after 22 years with the company.
R.Braegger--VB